A new study shows that older adults with type 2 diabetes who start treatment with sodium–glucose cotransporter-2 (SGLT-2) inhibitors—such as empagliflozin (Jardiance) and dapagliflozin (Farxiga)—or glucagon-like peptide-1 (GLP-1) receptor agonists—such as semaglutide (Ozempic) and liraglutide (Victoza)—experience slower progression of frailty over one year compared with those starting other diabetes medications. The findings suggest these therapies could help older adults maintain strength, mobility, and independence beyond their well-known effects on blood sugar and heart health.

Robert Wood Johnson University Hospital (RWJUH), an RWJBarnabas Health facility, in partnership with Rutgers Robert Wood Johnson Medical School (RWJMS), has been designated a National Rare Disease Center of Excellence by the National Organization for Rare Disorders (NORD). RWJUH is the first hospital in the state to receive this designation making New Jersey one of just 26 states in the U.S. to host such a Center of Excellence.